Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

K. Fizazi; N. Shore; M. Smith; J. Carles; T. Lebret; V. Lietuvietis; H. Mahammedi; A. Rannikko; E. Vjaters; P. Werbrouck; M. Miskic; I. Kuss; M. Le Berre; G. Borghesi; T. Sarapohja; S. Fayerabend

doi:10.1016/S0302-2838(21)01597-9

Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

K. Fizazi, N. Shore, M. Smith, J. Carles, T. Lebret, V. Lietuvietis, H. Mahammedi, A. Rannikko, E. Vjaters, P. Werbrouck, M. Miskic, I. Kuss, M. Le Berre, G. Borghesi, T. Sarapohja, S. Fayerabend

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	P1226
Pages (from-to)	S1740-S1741
Number of pages	2
Journal	European Urology
Volume	79
Issue number	Supplement 1
DOIs	https://doi.org/10.1016/S0302-2838(21)01597-9
Publication status	Published - Jun 2021
Externally published	Yes
Event	36th Annual European Association of Urology (EAU) Congress - Virtual Duration: 8 Jul 2021 → 13 Jul 2021 Conference number: 36 https://www.urotoday.com/calendar-events/492.html

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0302-2838(21)01597-9

https://www.europeanurology.com/article/S0302-2838(21)01597-9/fulltext

Cite this

Fizazi, K., Shore, N., Smith, M., Carles, J., Lebret, T., Lietuvietis, V., Mahammedi, H., Rannikko, A., Vjaters, E., Werbrouck, P., Miskic, M., Kuss, I., Le Berre, M., Borghesi, G., Sarapohja, T., & Fayerabend, S. (2021). Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study. European Urology, 79(Supplement 1), S1740-S1741. Article P1226. https://doi.org/10.1016/S0302-2838(21)01597-9

@article{1c30ac47893d478daf38b339996d0e04,

title = "Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study",

author = "K. Fizazi and N. Shore and M. Smith and J. Carles and T. Lebret and V. Lietuvietis and H. Mahammedi and A. Rannikko and E. Vjaters and P. Werbrouck and M. Miskic and I. Kuss and {Le Berre}, M. and G. Borghesi and T. Sarapohja and S. Fayerabend",

year = "2021",

month = jun,

doi = "10.1016/S0302-2838(21)01597-9",

language = "English",

volume = "79",

pages = "S1740--S1741",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "Supplement 1",

note = "36th Annual European Association of Urology (EAU) Congress, EAU 2021 ; Conference date: 08-07-2021 Through 13-07-2021",

url = "https://www.urotoday.com/calendar-events/492.html",

}

Fizazi, K, Shore, N, Smith, M, Carles, J, Lebret, T, Lietuvietis, V, Mahammedi, H, Rannikko, A, Vjaters, E, Werbrouck, P, Miskic, M, Kuss, I, Le Berre, M, Borghesi, G, Sarapohja, T & Fayerabend, S 2021, 'Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study', European Urology, vol. 79, no. Supplement 1, P1226, pp. S1740-S1741. https://doi.org/10.1016/S0302-2838(21)01597-9

Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study. / Fizazi, K.; Shore, N.; Smith, M. et al.
In: European Urology, Vol. 79, No. Supplement 1, P1226, 06.2021, p. S1740-S1741.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

AU - Fizazi, K.

AU - Shore, N.

AU - Smith, M.

AU - Carles, J.

AU - Lebret, T.

AU - Lietuvietis, V.

AU - Mahammedi, H.

AU - Rannikko, A.

AU - Vjaters, E.

AU - Werbrouck, P.

AU - Miskic, M.

AU - Kuss, I.

AU - Le Berre, M.

AU - Borghesi, G.

AU - Sarapohja, T.

AU - Fayerabend, S.

N1 - Conference code: 36

PY - 2021/6

Y1 - 2021/6

UR - https://www-webofscience-com.db.rsu.lv/wos/woscc/full-record/WOS:000674144301497

U2 - 10.1016/S0302-2838(21)01597-9

DO - 10.1016/S0302-2838(21)01597-9

M3 - Meeting Abstract

SN - 0302-2838

VL - 79

SP - S1740-S1741

JO - European Urology

JF - European Urology

IS - Supplement 1

M1 - P1226

T2 - 36th Annual European Association of Urology (EAU) Congress

Y2 - 8 July 2021 through 13 July 2021

ER -

Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this